Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

NCT04905069 · View on ClinicalTrials.gov ↗

Study Summary

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

Conditions Studied

Interventions

  • DEVICE SpaceOAR Vue System

Study Locations (20)

Other

  • Institut de Radiothérapie & Radiochirurgie HARTMANN — Levallois-Perret
  • MEDICLIN Robert Janker Klinik — Bonn
  • Klinikum Nurnberg Nord — Nuremberg
  • Bon Secours Radiotherapy Cork — Cork
  • Azienda Ospedaliero Universitaria di Parma — Parma
  • Policlinico Universitario Agostino Gemelli — Rome
  • IRCCS Ospedale Sacro Cuore Don Calabria — Verona
  • Hospital Universitario Cruces — Barakaldo
  • GenesisCare, Hospital San Francisco de Asis — Madrid

Florida

  • GenesisCare USA — Fort Myers
  • Florida Urology Partners, LLC — Tampa

Kansas

  • Kansas University Medical Center — Kansas City

Michigan

  • GenesisCare USA — Troy

New Jersey

  • New Jersey Urology, a Summit Health Company — Bloomfield

Pennsylvania

  • University of Pittsburgh Medical Center — Pittsburgh

South Carolina

  • Dr. John Sylvester — Myrtle Beach

New South Wales

  • Calvary Mater Newcastle — Waratah

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2021-12-21
Est. Completion 2030-04
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04905069

The ClinicalTrials.gov registry entry for NCT04905069 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention — of which SpaceOAR Vue System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04905069 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, Florida, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04905069 about?

NCT04905069 is a clinical study titled "Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer". To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

What is the current status of trial NCT04905069?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2021-12-21. Estimated completion is 2030-04.

What conditions does trial NCT04905069 study?

This clinical trial studies the following conditions: Prostate Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04905069?

The interventions under investigation include: SpaceOAR Vue System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04905069?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04905069 being conducted?

This trial has 20 study locations across Florida, Kansas, Michigan, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial